NICE wants more long-term info to change its 'mind' about Bayer's Xarelto
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal for England and Wales, again wants more information from Bayer on Xarelto (rivaroxaban), this time when used for deep vein thrombosis and pulmonary embolism. The institute wants to know more about how the drug when used as a long term treatment option.